Article Top Ad
Reading Time: 2 minutes

Las Vegas, Nevada–(Newsfile Corp. – April 27, 2022) – IFAN FINANCIAL Inc. (OTC PINK: IFAN), IFAN begins discussions with 503b lab to manufacture and distribute a proprietary psychedelic Ketamine product for IFAN.

IFAN looks forward to opening clinics focused on mental health. The psychedelic industry’s market is over $240B. Depression is a common mental disorder. Globally, it is estimated that 245 million adults suffer from depression worldwide. Ketamine is set up to help with mental health, PSTD and anxiety. Ketamine is one of the only psychedelics that can be prescribed by a physician. This provides a unique position for IFAN in the marketplace by focusing on functional medicine.

By focusing on a functional medical compound, we can provide customized service to the mental health industry and establishing ourselves in the psychedelics marketplace as a public company. “This business model we believe will be beneficial to our shareholders” said Larry Williams, CEO.

About IFAN Financial, Inc. (OTC Pink: IFAN) a Nevada holding corporation is in the mental health and bioceutical industry. IFAN Financial, Inc. (OTC Pink: IFAN) is an OTC Markets listed issuer and trades under the ticker symbol “IFAN”.

For more information about the Company visit:
Our OTC Markets Profile:
Our website is:
Our Twitter account is:


This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts, including, without limitation, statements regarding the investment offerings and the terms thereof, are forward-looking statements. When used in this press release, words such as we “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “should”, or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

[email protected]

Mark Anderson

To view the source version of this press release, please visit

Powered by WPeMatico